secwatch.observer — SEC 8-K summary
======================================

Issuer:     HAEMONETICS CORP (HAE)
CIK:        0000313143
Form:       8-K
Filed at:   2024-12-03T23:59:59+00:00
Accession:  0000313143-24-000066
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Haemonetics sells whole blood assets to GVS for $44.6M cash plus up to $22.5M earnout
--------------------------------------------------------------------------------

- Total consideration up to $67.1M: $44.6M cash at close plus up to $22.5M contingent on sales growth and milestones.
- Assets sold include whole blood collection, processing, and filtration portfolio, plus Covina, CA manufacturing facility and Tijuana, Mexico equipment.
- Haemonetics retains its apheresis line for automated blood collection (platelets, plasma, red cells).
- Transaction expected to close in Q1 2025, subject to customary closing conditions.
- GVS (not publicly traded) is a filter-solutions manufacturer in healthcare and life sciences.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/313143/000031314324000066/0000313143-24-000066-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/313143/000031314324000066/hae-20241203.htm
  HTML page:      https://secwatch.observer/filing/0000313143-24-000066

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer